News

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 6, 2020.

The drug’s Prescription Drug User Fee Act date is set for October 20, 2020.

Third year neurology resident Mona Al Banna, MB BCh BAO, MSc(Res) recounts her first major medical conference experience and provides guidance on how to make the most of your attendance, especially as a resident or fellow.

The associate professor in the department of neurology at the University of Colorado and neurologist at Advanced Neurology of Colorado discussed the advantages of cladribine and details of the ongoing CLICK-MS study.

Compared with intensive care units or normal wards, stroke units were associated with reduced mortality in patients with intracranial hemorrhage.

A 6136-patient comparative study of fingolimod, rituximab, and natalizumab suggested that the former was associated with a borderline‐significant increased risk of cancer compared to the general population.

The director of the Parkinson's Disease and Movement Disorders Center of Boca Raton spoke to how a new generation of interventions has led to a shifting backdrop in the field of care in essential tremor.

Patients with relapsing multiple sclerosis showed declining scores on tests of cognitive processing speeds from baseline to 3-month follow-up post-relapse.

The chief executive officer of Clene Nanomedicine discussed CNM-Au8, their novel investigational drug that will be used in the world’s first platform trial of potential ALS treatments.

Similar effects were observed for each proxy SMPS component when compared with placebo.

When performed by itself, endovascular therapy had greater rates of intracranial hemorrhage compared to a combination of both endovascular therapy and intravenous thrombolysis.

An overview on the Peer Exchange series, "Managing OFF Episodes in Parkinson disease."

The director of the Parkinson's Disease and Movement Disorders Center of Boca Raton spoke to the challenges which remain in addressing OFF episodes in treating Parkinson disease.

The drug was previously approved for the treatment of acute repetitive seizures and granted 7 years of orphan drug exclusivity in January 2020.

This included the first 34 participants from the VISIONARY-MS study, which is currently ongoing with the orally delivered suspension of clean-surfaced, faceted gold nanocrystals.

Addressing risk factors early on may help curb the negative effects of cerebral small vessel disease on aging and reduce risk of neurovascular events.

NeurologyLive's editor in chief Stephen D. Silberstein, MD, discussed the ways to optimizing patient care.

The NeuroEyeCoach visual rehabilitation therapy applied after stroke or other traumatic brain injury (TBI) improved vision in over 80 percent of patients

Gaboxadol is the first treatment in 50 years associated with positive change in outcomes in Angelman syndrome.

Data from the CLARITY extension trial suggest that the durability of treatment with cladribine extended beyond 24 months in those with relapsing-remitting multiple sclerosis.

Neurology News Network for the week ending February 29, 2020.

The president and founder of Cure Rare Disease discussed the company’s custom therapeutics for patients with rare diseases, including the use of CRISPR gene-editing technology to develop treatments for Duchenne muscular dystrophy.

Recovery status may be a useful tool to predict long-term outcomes in patients with relapsing forms of multiple sclerosis.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 28, 2020.

Leaders of the CMSC Working Group on MRI protocols and clinical guidelines express the need for a unified approach to diagnosing and monitoring multiple sclerosis.

The investigational MS therapy is currently under review with the FDA, with a PDUFA date set for June 2020.

The neurologist at Cleveland Clinic’s Lou Ruvo Center for Brain Health spoke to the need for data on the proper sequencing strategies for patients with MS who are switching disease-modifying therapies.

Rimegepant, the only orally disintegrating anti-CGRP tablet, marketed as Nurtec ODT, will be available in a 75-mg dose.